OncoSynergy and CMC Biologics Enter into Agreement for OS2966 Drug Program

OncoSynergy and CMC Biologics enter into agreement to develop and manufacture material for IND enabling studies and phase I clinical trials. This work will advance OncoSynergy’s OS2966 monoclonal antibody drug platform based on its “Targeted Synergy” approach — a transformative strategy allowing single drug inhibition of multiple fundamental cancer growth and treatment resistance mechanisms. OS2966 is being developed for glioblastoma, an aggressive, therapy resistant brain cancer.

For more information, please see the official joint news release.